Page 14 - Aadi Bioscience News Today

General trends in life sciences M&A Although the COVID-19 pandemic that defined 2020 continued to shape much of the life sciences industry in 2021, the way that it did was markedly...

Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news ...

Takeda Pharmaceutical won FDA approval for Livtencity, an antiviral developed to treat cytomegalovirus infection in transplant patients. The agency also approved an Aadi Biosciences drug, making it the first therapy authorized for treating a rare type of soft-tissue cancer.

Fyarro (sirolimus protein-bound particles [albumin-bound]) has been approved for adults with locally advanced unresectable or metastatic malignant PEComa.

Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) - read this article along with other careers information, tips and advice on BioSpace

Nab-sirolimus approved for locally advanced unresectable or metastatic malignant PEComa

LOS ANGELES, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on...

/PRNewswire/ -- Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in...

NEW YORK, June 10, 2021 -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights...

/PRNewswire/ -- Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in...